Literature DB >> 3208433

Skin collagen from scleroderma patients before and after cyclosporin A treatment.

C Francès, M C Branchet, O Blétry, C Lefevre, S Boisnic, P Kern, P Godeau.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3208433     DOI： 10.1111/j.1365-2230.1988.tb00637.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN： 0307-6938            Impact factor:   3.470


× No keyword cloud information.
  6 in total

1.  Suppression of T Cell Activation and Collagen Accumulation by an Anti-IFNAR1 mAb, Anifrolumab, in Adult Patients with Systemic Sclerosis.

Authors:  Xiang Guo; Brandon W Higgs; Anne C Bay-Jensen; Morten A Karsdal; Yihong Yao; Lorin K Roskos; Wendy I White
Journal:  J Invest Dermatol       Date:  2015-05-20       Impact factor: 8.551

Review 2.  Calcineurin inhibitors in systemic sclerosis - a systematic literature review.

Authors:  Nina N Hofmann; Robert A Ambühl; Suzana Jordan; Oliver Distler
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-05-19       Impact factor: 3.625

3.  Scleroderma renal crisis as a possible complication of cyclosporin A withdrawal.

Authors:  P Casoli; C Carretti; B Tumiati
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

Review 4.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 5.  Human autoimmune diseases are specific antigen-driven T-cell diseases: identification of the antigens.

Authors:  Chris D Platsoucas; Emilia L Oleszak
Journal:  Immunol Res       Date:  2007       Impact factor: 4.505

Review 6.  The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review.

Authors:  Cecilia Beatrice Chighizola; Voon H Ong; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 10.817
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.